



**Institutional Review Board of the University of Hong Kong/
Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB)**

Address: Rm 901, Administration Block, QMH Tel 2255 3923 2255 4086 Fax 2255 4735

Prof. YL Kwong
Medicine
Queen Mary Hospital
01-Nov-11

Dear Prof. Kwong,

IRB Reference Number: **UW 11-400**

The HKU/HA HKW IRB is authorized by a joint agreement of the University of Hong Kong and Hospital Authority Hong Kong West Cluster to review and monitor clinical research. It serves to ensure that research complies with the Declaration of Helsinki and acts in accordance to ICH GCP guidelines, local regulations and Hospital Authority and the University policies.

I write to inform that your research application/submission has been approved by an expedited process with details shown below. You are also requested to adhere to the conditions listed.

- Protocol title** : A multi-center international hospital-based case-control study of lymphoma in Asia (AsiaLymph)
- Study site(s)** : Queen Mary Hospital
- IRB reviewer** : Professor Virginia Wong, Chairman of the HKU/HA HKW IRB
- Document(s) approved** :
- : 01. Clinical research ethics review application form
 - : 02. Research protocol (July 16, 2011)
 - : 03. Informed consent for cases - English and Chinese
 - : 04. Informed consent for controls - English and Chinese
 - : 05. Body type as a child - English and Chinese
 - : 06. Surgical history - English and Chinese
 - : 07. Questionnaire on Health, Genes and Environment (Traditional Chinese Version - April 27, 2011) Hong Kong Study Center - English and Chinese
- Document(s) reviewed** : 08. Short CV of principal investigator

- (Conditions :
1. Do not deviate from, or make changes to the study protocol without prior written IRB approval, except when it is necessary to eliminate immediate hazards to research subjects or when the change involves only logistical or administrative issues.
 2. Report the following to HKU/HA HKW IRB: (i) study protocol or consent document change (use 'HKU/HA HKW IRB RE001F7'), (ii) serious adverse event (use 'HKU/HA HKW IRB RE001F8'), (iii) study progress (use 'HKU/HA HKW IRB RE001F9a')* (iv) new information that may be relevant to a subject's willingness to continue participation in the study.
 3. Report study progress to HKU/HA HKW IRB at a 12-monthly interval until study closure.)

Yours sincerely,

Mr. Chris Yip
HKU/HA HKW IRB Secretary